Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BioSante Pharmaceuticals Comments On Benefits Of Testosterone Use In HIV-Infected Women
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), which is developing a testosterone gel (LibiGel®) for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, today commented on a paper published in the May 15, 2009 issue of AIDS, the Journal of the International AIDS Society, on the effect of testosterone in women infected with HIV. The peer-reviewed journal reported results of a randomized, placebo-controlled trial of testosterone in HIV-infected women indicating that long-term testosterone administration was well tolerated in HIV-infected women and resulted in significant improvement in body composition, bone mineral density (BMD), and quality of life indices.
generic viagra online
House Education-Labor Panel Passes Health Reform Bill, Rejects Amendments To Ban Abortion Coverage
The House Education and Labor Committee on Friday voted 26-22 to approve the House health reform bill (HR 3200) after adopting 20 amendments, many of which sought to expand the scope of coverage and increase the number of U.S. residents eligible for purchasing coverage through a health insurance exchange, CQ Today reports. The panel voted 19-28 to reject two amendments offered by Rep. Mark Souder (R-Ind.) that would have precluded plans participating in the health insurance exchange -- including the proposed public insurance plan -- from covering abortion services. The committee agreed to allow some existing state and federal programs to obtain waivers from the bill"s requirements. Among the approved amendments was a 400-page amendment by committee Chair George Miller (D-Calif.) that would open the exchange to more small businesses, certain retirees, and families whose premiums and out-of-pocket costs total more than 11% of their income. The amendment was adopted by voice vote (Demirjian, CQ Today, 7/17).
News of the day
Advanced Prostate Cancer - New Review On PROSTVAC(TM) Published By Key Investigators From NCI
A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far.
Oncology

Cancer Therapeutics, Inc.'s Partner NanoTherapies, Inc. Utilizes Revolutionary Solution For Disrupting And Treating Cancer

Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced its new partner, NanoTherapies, Inc., is utilizing calcium phosphate nanoparticles to detect and treat cancer. These particles are about 350 times smaller than a human cell while providing both a safe and effective way to transport drugs and imaging materials into diseased cells. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). NanoTherapies has all rights to manufacturing technologies and intellectual property required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability. Calcium phosphate is a major component of bones. NanoTherapies" calcium phosphate NanoJackets clear the kidneys and liver without impact. They exit the body via the colon, and their chemical properties enable them to circulate in the bloodstream for prolonged periods yet dissolve in diseased cells, thereby releasing the drug. Metallic, silicon and carbon based nanoparticles cannot make the same claims regarding biocompatibility for humans nor do they have the chemical or physical properties that allow effective drug release in diseased cells. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense. Early lab studies show a ten-fold reduction in toxicity with a seven-fold increase in effectiveness for drugs delivered using NT"s technology. This means dramatically reduced side-effects owing to the severe toxicity of cancer drugs and increased effectiveness because the half-life of the drug is increased from minutes to hours. Most cancer drugs kill all the cells they contact and dissipate in less than thirty minutes. NT"s nanojackets encapsulate the drugs for up to thirty hours before being cleared from the body or until the nanoparticle enters a cancerous cell and release the drug. NT"s technology moves drug delivery strategies from carpet-bombing to smart-bombing with the corresponding dramatic decrease in collateral damage. In the same way NT"s nanoparticles deliver drugs to cancerous cells they can also transport imaging dyes that fluoresce under near infrared light to reveal cancerous cells. Imaging cancer at the cellular level enables new methods of early detection of cancer as well as post-treatment and post-operative evaluation. Cancer Therapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009